{"version":"1.0","type":"link","title":"Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study.","author_name":"Van Nieuwenhuysen E 외","author_url":"https://prs-insight.online/author/Van%20Nieuwenhuysen%20E","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/167154","thumbnail_width":1200,"thumbnail_height":630}